Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ironwood Pharmaceuticals, Inc.
< Previous
1
2
Next >
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
August 08, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
July 25, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
May 21, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
May 09, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
May 06, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
May 01, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
April 25, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
March 28, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
February 29, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
February 23, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
February 15, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
February 01, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
January 08, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
January 08, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
December 12, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
November 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
October 26, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
October 23, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
October 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
October 05, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
August 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
July 25, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
June 29, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
VECT
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
June 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
VECT
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
June 12, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 22, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Tickers
IRWD
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit